Andere Sprachen Coya Therapeutics, Inc.

Aktien

A3DZRY

US22407B1089

COYA

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:20:37 04.06.2024			% 5 Tage	% 1. Jan.
7,395 ^USD	-1,40 %		-5,66 %	-1,08 %

22.05.	Coya Therapeutics gibt den Abschluss einer kontrollierten Phase-2-Studie mit niedrig dosiertem Interleukin-2 (LD IL-2) bei Patienten mit Alzheimer-Krankheit bekannt	CI
20.05.	Coya Therapeutics erhält 5 Millionen Dollar Kapitalbeteiligung von der Alzheimer's Drug Discovery Foundation	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology	03.06.
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index	28.05.
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients with Alzheimer's disease	23.05.
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease	22.05.
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease	22.05.
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	20.05.
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)	20.05.
Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation	20.05.
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	17.05.
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results	09.05.
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	26.04.
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit	22.04.
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit	18.04.
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	08.04.
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results	19.03.
Coya Therapeutics to Participate in BTIG Fireside Discussion	12.03.
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12.03.
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Coya Therapeutics, Inc.

Aktien

A3DZRY

US22407B1089

COYA

Andere Sprachen

Filter